2N Pharma’s mission is to bring new effective therapies to patients with ALS and other neurodegenerative diseases by focusing on fatty acid metabolism as the common pathogenic mechanism.
2N Pharma is a small biotech company that was founded in 2019 by Preben Bruun-Nyzell (CEO) and John Nieland (COO). 2N Pharma is proud to have joined the BioInnovation Institute’s Creation House Program, joining a stable of life science innovators, helping accelerate our research and bring treatments rapidly to market.
The mission is to bring new effective therapies to patients with ALS and other neurodegenerative diseases.